This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Corrigendum to "Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies" [Breast 41S1 (2018) S11–12]. (February 2020)
Record Type:
Journal Article
Title:
Corrigendum to "Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies" [Breast 41S1 (2018) S11–12]. (February 2020)
Main Title:
Corrigendum to "Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies" [Breast 41S1 (2018) S11–12]